SAFC today announced an extension to Sigma-Aldrich’s proprietary CompoZr® Zinc Finger Nuclease (ZFN) platform that will expand the availability of ZFN-based technology to include off-the-shelf ZFNs and custom cell engineering services for use in the biopharmaceutical industry.
Archive for the ‘ACF’ Category
News Alert: SAFC Extends Gene Editing Technology Platform with Readily-Available Zinc Finger Nuclease Products and Services
Wednesday, November 10th, 2010Lenexa next as SAFC invests in developing Center of Excellence for seamless dry powder media and reagents production
Tuesday, May 4th, 2010ON April 27th SAFC® announced a $6.25 million investment program to expand its Lenexa, KS. facility, creating a global ‘Center of Excellence’ for the seamless upstream and downstream production of dry powder media and reagents. The investment, part of SAFC’s worldwide facilities initiative, is designed to better serve the biopharmaceutical industry by creating ‘Centers of Excellence’ for manufacturing and supply chain optimization.
The project, supported by a $250,000 economic development grant from the Kansas Bioscience Authority, will include expanded pin milling and blending capabilities, enabling an increase of approximately 30% in batch production capacity. The expansion is expected to be completed by the end of 2010.
A Risk-Based Approach to Establishing Animal Component Free (ACF) Facilities
Monday, February 22nd, 2010In this ‘Vendor Voice’ article from December 2009’s BioProcessing International, Thomas Pamukoglu from SAFC Biosciences maps out the step-by-step process that the company went through at its Lenexa, KS facility in order to become ACF.
